Carcinogenesis, Vol 18, 989-994, Copyright © 1997 by Oxford University Press
SN Perkins, SD Hursting, DC Haines, SJ James, BJ Miller and JM Phang
Transgenic mice with both alleles of the p53 tumor suppressor gene product
'knocked out' by gene targeting are susceptible to early development of
tumors, chiefly lymphomas and sarcomas. Compared with the control group,
administration of dehydroepiandrosterone (DHEA) at 0.3% of the diet to male
p53-deficient mice extended their lifespan by delaying death due to
neoplasms (from 105 to 166 days on study, P = 0.002), primarily by
suppressing lymphoblastic lymphoma (from 45 to 6% of neoplastic deaths, P =
0.010). Treatment with a synthetic DHEA analog,
16alpha-fluoro-5-androsten-17-one (compound 8354), at 0.15% of the diet
also increased lifespan, to 140 days for mice that developed tumors (P =
0.037). The effects of these steroids on lifespan and tumor development did
not appear to be strongly related to inhibition of food consumption and
weight gain, in that a group pair-fed with control diet to the reduced food
consumption of the DHEA-treated group developed and died of the same types
of neoplasms at the same rate as the controls fed ad libitum. The
chemopreventive effect of these steroids has been proposed to be due to
suppression of DNA synthesis by inhibition of glucose 6-phosphate
dehydrogenase, the rate-limiting enzyme of the pentose phosphate pathway.
Although DHEA and its analog are strong non- competitive inhibitors of this
enzyme in vitro, treatment with DHEA did not deplete cellular nucleotide
pools in the liver, as would have been predicted. The chemopreventive
effect of DHEA in this model may be due to steroid-induced thymic atrophy
and suppression of T cell lymphoma, permitting these mice to survive long
enough to develop tumors with longer latency.
ARTICLES
Chemoprevention of spontaneous tumorigenesis in nullizygous p53- deficient mice by dehydroepiandrosterone and its analog 16alpha-fluoro- 5-androsten-17-one
Laboratory of Nutritional and Molecular Regulation, SAIC, National Cancer Institute-Frederick Cancer Research and Development Center, MD 21702-1201, USA.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. P. Burgess, J. S. Green, J. M. Hill, Q. Zhan, M. Lindeblad, A. Lyubimov, I. M. Kapetanovic, A. Schwartz, and B. F. Thomas Identification of [14C]Fluasterone Metabolites in Urine and Feces Collected from Dogs after Subcutaneous and Oral Administration of [14C]Fluasterone Drug Metab. Dispos., May 1, 2009; 37(5): 1089 - 1097. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. McCormick, W. D. Johnson, N. M. Kozub, K.V.N. Rao, R. A. Lubet, V. E. Steele, and M. C. Bosland Chemoprevention of rat prostate carcinogenesis by dietary 16{alpha}-fluoro-5-androsten-17-one (fluasterone), a minimally androgenic analog of dehydroepiandrosterone Carcinogenesis, February 1, 2007; 28(2): 398 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Arnold and M. R. Blackman Does DHEA Exert Direct Effects on Androgen and Estrogen Receptors, and Does It Promote or Prevent Prostate Cancer? Endocrinology, November 1, 2005; 146(11): 4565 - 4567. [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Patel, N. P. Nunez, S. N. Perkins, J. C. Barrett, and S. D. Hursting Effects of Energy Balance on Cancer in Genetically Altered Mice J. Nutr., December 1, 2004; 134(12): 3394S - 3398S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Misra, S. D. Hursting, S. N. Perkins, N. Sathyamoorthy, J. C. Mirsalis, E. S. Riccio, and J. A. Crowell Genotoxicity and Carcinogenicity Studies of Soy Isoflavones International Journal of Toxicology, July 1, 2002; 21(4): 277 - 285. [Abstract] [PDF]
|
|
|
|
 |
|
 H. P. Ciolino, C. J. MacDonald, and G. C. Yeh Inhibition of Carcinogen-activating Enzymes by 16{alpha}-Fluoro-5-androsten-17-one Cancer Res., July 1, 2002; 62(13): 3685 - 3690. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Simile, M. R. De Miglio, D. Calvisi, M. R. Muroni, M. Frau, G. Asara, L. Daino, L. Deiana, R. M. Pascale, and F. Feo Long-term dehydroepiandrosterone and 16{{alpha}}-fluoro-5-androsten-17-one administration enhances DNA synthesis and induces expression of c-fos and c-Ha-ras in a selected population of preneoplastic lesions in liver of diethylnitrosamine-initiated rats Carcinogenesis, February 1, 2001; 22(2): 301 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-M. Zhang, T.-Y. Wong, L.-Y. Chen, C.-S. Lin, and J.-K. Liu Induction of a Futile Embden-Meyerhof-Parnas Pathway in Deinococcus radiodurans by Mn: Possible Role of the Pentose Phosphate Pathway in Cell Survival Appl. Envir. Microbiol., January 1, 2000; 66(1): 105 - 112. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. P. Ciolino and G. C. Yeh The Steroid Hormone Dehydroepiandrosterone Inhibits CYP1A1 Expression in Vitro By a Post-transcriptional Mechanism J. Biol. Chem., December 3, 1999; 274(49): 35186 - 35190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Hursting, T. J. Slaga, S. M. Fischer, J. DiGiovanni, and J. M. Phang Mechanism-Based Cancer Prevention Approaches: Targets, Examples, and the Use of Transgenic Mice J Natl Cancer Inst, February 3, 1999; 91(3): 215 - 225. [Abstract] [Full Text] [PDF]
|
|